Understanding clinical therapies on cognitive function is an important aspect of the drug discovery process. Objective cognitive testing (not based on self-reported measures) in early phase clinical trials could provide insight to subtle but important effects on a subject’s ability to perceive, process, understand and store information, make decisions and produce appropriate responses.
This understanding can benefit the drug discovery process by informing decisions to progress candidate compounds, dose-response relationships, selection of safe doses, detection of off-target effects and risk: benefit to the target indication.
Cognitive testing can be deployed at pre-screening to ensure you have appropriate participants on your study and in-study to assess compound effects on different cognitive domains such as:
- Memory and recall
- Processing/reaction speed
- Speech and language
- Attention/Executive functions
Contact us to discuss any cognitive testing you need for your clinical trial.
The Science Behind CRS can help Sponsors and CROs with some of these challenges in Phase 1 trials by providing the tools and specialist expertise to answer key questions in relation to safety and efficacy when bringing novel drug candidates to human clinical trials.